ADVERTISEMENT
ADVERTISEMENT

New England Biolabs releases “Induro™ Reverse Transcriptase” — offering a novel approach to cDNA synthesis

New enzyme delivers new performance standard for cDNA synthesis reactions to help overcome barriers in RNA-sequencing workflows

New England BioLabs

A leading approach of direct RNA sequencing (RNA-seq) involves first converting RNA into an RNA/cDNA hybrid molecule using a reverse transcriptase (RT) — a DNA polymerase enzyme that transcribes single-stranded RNA into complementary DNA (cDNA). cDNA synthesis is the first step in many molecular biology workflows, including gene expression studies using real-time PCR. To accomplish this, an ideal RT would exhibit high processivity and generate high cDNA yields.

To address this need, NEB recently introduced its Induro  Reverse Transcriptase — uniquely formulated as a group II intron-encoded RT that exhibits high processivity, increased thermostability, and increased tolerance of inhibitors in the synthesis of cDNA from RNA. It is an ideal enzyme for challenging cDNA synthesis from long transcripts, RNAs with strong secondary structures, and RNA samples with inhibitors. With improved 5 sequencing coverage of long transcripts, Induro RT can enable RNA-seq applications such as direct RNA and long read cDNA sequencing workflows — leading to more accurate transcriptome analysis.

A summary of Induro’s advantages include:

  • Rapid generation of high yields of long cDNA 
  • Strong inhibitor tolerance enabling robust cDNA synthesis performance
  • Direct support for RNA sequencing and long read cDNA sequencing workflows
  • cDNA generation at higher temperatures, ideal for challenging sample types
  • Comparable fidelity to retroviral RTs
ADVERTISEMENT